Silencing HMGCS2 and PPARα inhibits NOX activity by reducing ketone body production and the metabolic burden of fatty acids. This results in a decrease in ROS production, alleviates OS, and ultimately mitigates myocardial injury and dysfunction in DCM. The gene discussed is HMGCS2; the disease is familial dilated cardiomyopathy.